Stay updated with breaking news from ஜொனாதன் அஸ்சஆஃ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Why Seelos Therapeutics Dived by 24% Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Imugene secures A$0.20 price target from Roth Capital Partners The company’s cohort review committee has confirmed that its Phase 1 NSCLC trial for checkpoint immunotherapy candidate PD1-Vaxx may proceed to the third and final dose cohort. Results from the Phase 2 HER-Vaxx trial in gastric cancer are expected this month. Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) welcomes a recent research report from Roth Capital Partners which maintains the company’s 12-month price target of $0.20 compared to the current price of A$0.155. The report author Jonathan Aschoff said the price target was based on a DCF analysis using a 30% discount rate applied to all cash flows and the terminal value - which is based on a 5x multiple of the projected FY2031 operating income of about A$1.6 billion. ....
Imugene Ltd secures A$0.20 price target from Roth Capital Partners proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.